ACIU 250117 5.00C (ACIU250117C5000) Stock Options, News & Quotes

0.05
0.000.00%

15min DelayTrading Dec 23 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 10 06:03

Update

$AC Immune (ACIU.US)$ Reuters· 3 mins ago
AC Immune SA - ACI-24.060 Safe and Well Tolerated in Down Syndrome Patients

Trytosaveabit

Nov 14 06:03

Update

$AC Immune (ACIU.US)$ Reuters· 2 mins ago
AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Jaguar8

Nov 14 06:02

NEWS

$AC Immune (ACIU.US)$
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
The trial rep...

amiable Hedgehog_758

Sep 17 06:34

$AC Immune (ACIU.US)$
AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
Benzinga· 10 mins ago5mins
AC Immune (ACIU.US)
3.270
3.530
+2.83%
+7.95%
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...

Trytosaveabit

Sep 17 06:09

News

$AC Immune (ACIU.US)$ Press Release: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
Dow Jones· 7 mins ago
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease